Mitochonic Acid 5

Mitochonic Acid 5 was discovered by screening an in-house library of analogs of the plant hormone indole-3-acetic acid for compounds that raise cellular ATP, using a hepatocellular carcinoma cell line as the readout ^[3]. The lead, MA-5, improved the stress survival of fibroblasts from patients with a range of mitochondrial diseases, including Leigh syndrome, MELAS, Leber hereditary optic neuropathy, and Kearns-Sayre syndrome, and it did so even when oxidative phosphorylation or the electron transport chain was pharmacologically inhibited, pointing to a mechanism outside the canonical respiratory pathway ^[3].

Subsequent work identified the molecular basis of this activity. MA-5 accumulates in mitochondria and binds mitofilin, also called Mic60, a protein of the crista junction on the inner membrane; through this interaction it facilitates oligomerization of ATP synthase and the assembly of respiratory supercomplexes, restoring crista shape and mitochondrial dynamics while increasing ATP and reducing reactive oxygen species ^[1]. In a broad panel of twenty-five patient fibroblast lines, twenty-four responded to MA-5, and the mitochondrial-stress biomarker GDF-15, elevated under oxidative stress, was significantly reduced by treatment both in cells and in a mitochondrial-disease mouse ^[1].

Therapeutic breadth has been shown across organ systems. MA-5 improved renal function in ischemia-reperfusion and cisplatin nephropathy models and ameliorated cardiac and renal mitochondrial respiration in Mitomice bearing mitochondrial DNA deletions ^[2]. It also rescued myoblasts and fibroblasts from patients with sporadic inclusion body myositis, reversing impaired ATP production and normalizing mitochondrial fusion and fission gene expression ^[4]. Across these studies MA-5 emerges as a mitochondria-homing small molecule that improves energy output structurally, by reshaping the ATP-synthesis machinery, rather than by adding an antioxidant or an electron carrier.

Preclinical only; broad cell and animal data across multiple organ systems

MA-5 is an investigational compound whose safety data come from cell and animal studies; no human clinical safety profile has been established. Its parent scaffold, indole-3-acetic acid, is a naturally occurring plant hormone, but that lineage does not confer human safety, and the difluorophenyl-substituted derivative is a distinct synthetic entity. It should be regarded as a research compound and not consumed. Developers have proposed GDF-15 as a biomarker to guide any future clinical testing.

MA-5 was created and characterized by Takaaki Abe and colleagues at Tohoku University in Japan, first reported in 2015 as a derivative of indole-3-acetic acid that enhances ATP production in mitochondrial-disease fibroblasts. Follow-up papers that same year and afterward elucidated its mitofilin-binding mechanism and demonstrated efficacy in renal, cardiac, and muscle disease models, establishing the compound and its associated GDF-15 biomarker as a coherent translational program aimed at mitochondrial and metabolic disease.

Within mitochondrial research MA-5 is admired for its distinctive structural mechanism, being one of the few small molecules shown to boost ATP by reorganizing the synthesis machinery rather than by antioxidant or electron-shuttle action. It is not known in consumer nootropic markets and has no commercial supplement presence. Its reputation is that of a mechanistically novel, preclinically promising candidate that has not yet entered mainstream clinical development.